



Vosevi

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
WS/2222	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a	07/07/2022	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS).</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p>				
SW/0055	Post Authorisation Safety Study results - EMEA/H/C/PSR/J/0038 – Variation	24/03/2022	30/05/2022	SmPC, Annex II and PL	The observational study and the systematic review/ meta-analysis did not show an increased risk of hepatocellular carcinoma recurrence in patients treated with direct-acting antivirals. The DAA-PASS study commitment is considered fulfilled and the respective products should be removed from the list of medicines under additional monitoring.
R/0053	Renewal of the marketing authorisation.	24/02/2022	29/04/2022	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vosevi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
PSUSA/10619 /202107	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir / voxilaprevir	10/02/2022	n/a		PRAC Recommendation - maintenance
IA/0051/G	<p>This was an application for a group of variations.</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>A.5.b - Administrative change - Change in the name</p>	04/11/2021	n/a		

	<p>and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p>				
IA/0052/G	<p>This was an application for a group of variations.</p> <p>B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure</p> <p>B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold</p>	27/10/2021	n/a		
WS/2157	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation</p>	30/09/2021	29/04/2022	Annex II	
X/0045/G	<p>This was an application for a group of variations.</p> <p>Extension application to introduce a new strength (200 mg /50 mg /50 mg film-coated tablets). The new presentation is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients</p>	22/07/2021	16/09/2021	SmPC, Annex II, Labelling and PL	

	<p>aged 12 years and older or weighing at least 30 kg, who cannot swallow the higher strength tablet.</p> <p>The extension application is grouped with an extension of indication to include paediatric use in patients aged 12 years and older and weighing at least 30 kg. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 5.0) is updated in accordance. Furthermore, the MAH took the opportunity to implement minor editorial updates in module 3.2.P and minor editorial updates throughout the Product Information, and to update the list of local representatives in the Package Leaflet.</p> <p>Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one</p>				
IG/1415	A.7 - Administrative change - Deletion of manufacturing sites	05/08/2021	n/a		
IG/1381	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	06/04/2021	n/a		

PSUSA/10619 /202007	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir / voxilaprevir	11/02/2021	n/a		PRAC Recommendation - maintenance
WS/1915	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Submission of the final report from study GS-US-248-0123, listed as a category 3 study in the RMP. This is a long-term observational follow-up registry of subjects who did not achieve sustained virologic response in Gilead-sponsored trials in subjects with chronic hepatitis C infection. The RMPs have also been submitted for each of the products in this work-sharing procedure (Harvoni v8.0, Eplusa v7.0 and Vosevi v4.0).</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p>	29/10/2020	n/a		
IB/0044	B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	09/10/2020	n/a		
IG/1275	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	18/08/2020	n/a		

II/0040/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> <p>B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>	16/07/2020	n/a		
IB/0041/G	<p>This was an application for a group of variations.</p> <p>B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold</p> <p>B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation</p>	03/07/2020	n/a		
IB/0039	B.II.f.1.b.1 - Stability of FP - Extension of the shelf	20/05/2020	21/04/2021	SmPC and	

	life of the finished product - As packaged for sale (supported by real time data)			Annex II	
IG/1247	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	08/05/2020	n/a		
IG/1248	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	30/04/2020	21/04/2021	SmPC and PL	
IA/0036/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p>	30/04/2020	n/a		

IG/1233	B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol	10/04/2020	n/a		
PSUSA/10619 /201907	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir / voxilaprevir	13/02/2020	n/a		PRAC Recommendation - maintenance
WS/1701	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.8 of the SmPC in order to add new safety information on rash and angioedema following a cumulative review of hypersensitivity with Eplclusa and Vosevi, prompted by routine pharmacovigilance and signal detection activities. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes throughout the Product Information.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	16/01/2020	21/04/2021	SmPC, Annex II, Labelling and PL	The CHMP considered that "rash" should be added to the Product Information as an adverse drug reaction with the frequency "common" (i.e. may affect up to 1 in 10 people) and "angioedema" as an adverse drug reaction with the frequency "uncommon" (i.e. may affect up to 1 in 100 people).
WS/1518	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the</p>	19/09/2019	04/11/2019	SmPC and PL	Sofosbuvir in a fixed dose combination with ledipasvir was administered for 12 weeks to 18 patients with genotype 1 chronic hepatitis C and severe renal impairment in an open-label study (Study 0154). The safety of sofosbuvir in a fixed dose combination with either ledipasvir or

SmPC (Eplclusa, Harvoni, Sovaldi) and 4.2, 4.4, 4.8 and 5.2 (Vosevi) in order to add new information regarding the use of the sofosbuvir-containing products in patients with renal impairment, based on final results from studies GS-US-342-4062, GS-US-337-4063 and GS-US-334-0154, listed as a category 3 study in the RMP and study GS-US-338-1125. Study GS-US-342-4062 was a phase 2, multi-centre, open-label study to evaluate the efficacy and safety of sofosbuvir/velpatasvir for 12 Weeks in subjects with chronic HCV infection who are on dialysis for end stage renal disease. Study GS-US-337-4063 was a phase 2, multi-centre, open-label study to evaluate the efficacy and safety of ledipasvir/sofosbuvir in subjects with genotype 1, 4, 5 and 6 chronic HCV infection who are on dialysis for end stage renal disease. Study GS-US-334-0154 was a phase 2b, open label study of 200 mg or 400 mg Sofosbuvir+ribavirin for 24 Weeks in Genotype 1 or 3 HCV infected subjects with renal insufficiency. Study GS-US-338-1125 was a phase 1, open-label, parallel-group, single-dose study to evaluate the pharmacokinetics of voxilaprevir in subjects with normal renal function and severe renal impairment.

The Package Leaflet is updated accordingly. The RMPs have also been submitted for each of the products in this work-sharing procedure.

C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance

velpatasvir has been studied in 154 patients with ESRD requiring dialysis (Study 4062 and Study 4063). In this setting, exposure of sofosbuvir metabolite GS-331007 is 20-fold increased, exceeding levels where adverse reactions have been observed in preclinical trials. In this limited clinical safety data set, the rate of adverse events and deaths was not clearly elevated from what is expected in ESRD patients.

The CHMP considered that safety data on the use of the sofosbuvir-based products in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m²) and end stage renal disease (ESRD) requiring haemodialysis are limited. Overall, the CHMP concluded that the sofosbuvir-based products can be used in these patients with no dose adjustment when no other relevant treatment options are available.

	data				
PSUSA/10619/201901	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir / voxilaprevir	25/07/2019	26/09/2019	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/10619/201901.
IB/0031/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch</p>	22/08/2019	n/a		

	<p>control/testing takes place</p> <p>B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place</p>				
WS/1613	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.5 of the SmPC in order to add new information regarding co-administration with atorvastatin, based on final results from study GS-US-342-4034.</p> <p>Study GS-US-342-4034 was a phase 1 study to evaluate the effect of sofosbuvir/velpatasvir fixed dose combination on the pharmacokinetics of atorvastatin.</p> <p>In addition, the Worksharing Applicant took the opportunity to amend Annex II of the Product Information with regards to the due date for submission of study DAA-PASS. This study is designed to evaluate the recurrence of hepatocellular carcinoma and the date has been postponed from Q2 2021 to Q2 2023.</p> <p>Furthermore, the MAH implemented minor editorial updates throughout the Product Information.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	25/07/2019	26/09/2019	SmPC, Annex II and PL	<p>Based on the results of study GS-US-342-4034, the CHMP concluded that no dose adjustments are needed during co-administration of Epclusa (sofosbuvir/velpatasvir) and atorvastatin (40 mg single dose).</p> <p>Furthermore, based on co-administration of Epclusa (sofosbuvir/velpatasvir) and atorvastatin and earlier experience with co-administration of Vosevi (sofosbuvir/velpatasvir/voxilaprevir) and other statins, the CHMP concluded that atorvastatin may be administered with Vosevi at a dose that does not exceed atorvastatin 20 mg.</p>

WS/1523	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.4 and 4.5 of the SmPC in order implement new information on the use of sofosbuvir-based therapy with concomitant drugs, based on final results from study GS-US-334-2130. This was a phase I study to evaluate the effects of cytochrome P450 and drug transporter inducers on sofosbuvir and probe drug pharmacokinetics in healthy subjects. Furthermore, section 4.3 of the Sovaldi SmPC was updated in order to remove the use of rifabutin as a contraindication.</p> <p>The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to introduce minor editorial changes throughout the Product Information.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	04/07/2019	26/09/2019	SmPC and PL	<p>Based on results from study GS-US-334-2130, effects of rifabutin and carbamazepine administration on the drug levels of sofosbuvir have been updated throughout the Product Information.</p> <p>With regards to the rifabutin interaction, a 28% reduction in sofosbuvir exposure was observed. Considering that reduction in sofosbuvir dose of <50% is expected to be safe in terms of potentially reduced efficacy, the CHMP concluded that the data support removal of co-administration of rifabutin as contraindication from the Sovaldi (sofosbuvir) Product Information. The contraindication is maintained for Eplclusa, Harvoni and Vosevi, given the lack of data on interactions with the other active substances contained in these combination products. The data available for interactions with carbamazepine indicated that sofosbuvir levels were reduced by 48%, but the confidence interval included the 50% value. Therefore, the CHMP considered that a cautionary approach should be taken and contraindication concerning co-administration of carbamazepine should be retained.</p> <p>Furthermore, the term "potent P-glycoprotein inducers" was replaced by "strong P-glycoprotein inducers" throughout the Product Information in line with terminology used in the EMA Guideline on the investigation of drug interactions.</p>
IB/0030/G	<p>This was an application for a group of variations.</p> <p>B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation</p> <p>B.II.f.1.e - Stability of FP - Change to an approved</p>	23/05/2019	n/a		

	stability protocol				
IG/1057	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	01/03/2019	n/a		
IG/1069	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority	28/02/2019	06/06/2019	SmPC and PL	
PSUSA/10619 /201807	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir / voxilaprevir	14/02/2019	n/a		PRAC Recommendation - maintenance
IB/0020	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	08/01/2019	06/06/2019	SmPC	
IG/1037	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	14/12/2018	06/06/2019	SmPC and PL	
II/0018	Update of section 5.1 of the SmPC based on final results from study GS-US-367-4181. This was an open-label study to evaluate the safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination for 12 weeks in subjects who participated in a prior Gilead-sponsored HCV treatment study.	13/12/2018	06/06/2019	SmPC	Further to assessment of data from study GS-US-367-4181, the CHMP concluded that new information related to adult patients previously treated with sofosbuvir/velpatasvir-containing regimens should be added, as follows: Vosevi for 12 weeks was evaluated in patients who were previously treated with a sofosbuvir/velpatasvir-containing

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				regimen. The median time to re-treatment was 414 days. Of the 31 patients enrolled, 74% were male, 81% were white, 71% had a baseline body mass index < 30 kg/m2, 48% had compensated cirrhosis, 58% had previously received sofosbuvir, velpatasvir and voxilaprevir, and 42% had previously received sofosbuvir and velpatasvir. Most subjects had genotype 1 (61%), 1a (48%), 1b 13% or genotype 3 (26%) HCV infection. The overall sustained virologic response rate at 12 weeks was 100%.
IB/0019	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	03/12/2018	n/a		
WS/1476	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Submission of the final report from study GS-US-334-0154, listed as a category 3 study in the RMP. This is a phase 2b randomized, open-label study of 200mg or 400mg sofosbuvir + ribavirin for 24 Weeks in genotype 1 or 3 HCV-infected subjects with renal insufficiency. The RMPs have also been submitted for each of the products in this work-sharing procedure.</p> <p>C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority</p>	29/11/2018	n/a		
PSUSA/10619 /201801	Periodic Safety Update EU Single assessment - sofosbuvir / velpatasvir / voxilaprevir	12/07/2018	n/a		PRAC Recommendation - maintenance

WS/1391	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 5.3 of the SmPC based on data from a 2-year rat carcinogenicity study TX-281-2030. In addition, the MAH took the opportunity to update the ATC code in line with the new classification of antivirals for treatment of HCV infections and to introduce minor linguistic amendments and typographical corrections throughout the Product Information.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	14/06/2018	06/06/2019	SmPC and PL	Velpatasvir was not carcinogenic in the 2-year rat carcinogenicity study at exposures at least 5-times higher than human exposure.
T/0015	Transfer of Marketing Authorisation	25/04/2018	07/06/2018	SmPC, Labelling and PL	
IG/0901	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	26/03/2018	n/a		
IA/0012	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	23/03/2018	n/a		
IB/0010/G	This was an application for a group of variations.	26/02/2018	n/a		

	<p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p>				
WS/1328/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p>	08/02/2018	n/a		
IB/0009	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	30/01/2018	n/a		

WS/1272	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation</p>	18/01/2018	n/a		
WS/1246/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation</p>	30/11/2017	n/a		
IG/0848/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder</p>	12/10/2017	n/a		

	or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
IG/0840/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting</p>	22/09/2017	n/a		

	<p>material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p>				
IA/0002	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	20/09/2017	n/a		
IAIN/0004/G	<p>This was an application for a group of variations.</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p>	19/09/2017	n/a		
IA/0001/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.I.b.1.b - Change in the specification parameters</p>	15/09/2017	n/a		

	and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits				
--	---	--	--	--	--